Health Care Select Sector SPDR Fund ETF (XLV) outperformed the S&P 500 in Q3 2024. Bristol-Myers led growth while Moderna ...

Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy ...

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...

FDA approves Bristol Myers' Opdivo for resectable non-small cell lung cancer, reducing recurrence risk by 42% and showing 70% 18-month event-free survival in patients.

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.

Shares of Prime Medicine, Inc. PRME were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb BMY. The collaboration ...

We estimate Bristol Myers Squibb’s Valuation to be $60 per share, reflecting around 20% upside from here. While BMY stock looks like it has ample room for growth, it is helpful to see how ...

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?